Staff perceptions of PRN medication in a residential care setting by Stubbings, Daniel R. et al.
1 
 
 
 
Staff Perceptions of PRN Medication in Clinical Practice 
When medication is administered ‘as needed’ or ‘when required’ it is referred to as PRN, 
which is the acronym for the Latin phrase Pro Re Nata. PRN psychotropic medication is 
administered in a variety of mental health settings (Wicher, Morrison, & Duglas-Hall, 2002) 
and should be done so in collaboration with the service user (Matthias, Salyers, Rollins & 
Frankel, 2012). However, the decision to use PRN is a subjective one based on the clinical 
views of the staff, the views and behaviour of the patient, the organisational policies and the 
legislation of the country. The National Institute for Health and Care Excellence (NICE, 
2014), the Royal Pharmaceutical Society of Great Britain (Royal Pharmaceutical Society, 
2007) and the Nursing and Midwifery Council’s (NMC) guidelines on medicines 
management all fall short of providing evidence-based guidance on how staff should make 
judgements about when psychotropic PRN medication is ‘needed’. 
Psychotropic medication is one of the most frequently used (Akram, Slavin & 
Davies, 2014; Ziguras et al., 1999) forms of treatment in mental health care settings. Due to 
an increasing population and long-term usage the financial costs have also been increasing 
(Ilyas & Moncrieff, 2012). It is a group of medications that effects mood, mental status, 
perceptions and/or physiological arousal (Kalachnik et al., 1995). It is estimated that 
approximately 70- 90% of residents within inpatient mental health settings receive this form 
of medication (Baker, Lovell, Harris & Campbell, 2007). Negative consequences of 
psychotropic medication can include prolonged institutionalisation (Centorrino et al., 2004; 
John et al., 2014) and increased mortality (Johnell, et al., 2016; Waddington, Youssef & 
Kinsella, 1998). Polypharmacy is not considered best medical practice (Kreyenbuhl, 2007), 
yet PRN is typically administered to service users who are already on an array of other 
psychotropic medication (Thapa, et al., 2003).  
Variations in administration practices between healthcare settings highlights 
potential concerns regarding PRN medication. Some treatment settings experience an 
increase in medication around the time of staff shift changes and institutions that are more 
restrictive use more medication (Curtis & Capp, 2003; Vander Stichele et al., 2006). These 
patterns suggest that PRN medication might be being used to eradicate problematic 
behaviour rather than to treat illness (Huybrechts et al., 2012; Stuart & Briesacher, 2002) 
and thus the needs of the institutions are being prioritised over the needs of the service users. 
But alternatively, it could be argued that such findings are because patients find changes in 
staffing groups distressing due to the changes in relational security and more medication is 
2 
 
 
 
used in restrictive environments because the patients are often more unwell. The lack of 
clarity around how and why staff make decisions around PRN administration is further 
obscured in most organisations by the lack of records documenting the reasons for 
administration (Geffen et al., 2002). Record keeping practice can also be poor regarding the 
monitoring and documentation of the effects on the service user after administration (Usher, 
Lindsay, & Sellen, 2001). 
 The evidence base for the effectiveness of PRN medication in psychiatric inpatient 
settings is limited and has been associated with greater risk of adverse consequence 
(Srivastava, 2009). Much of the existing research surrounding psychotropic medication has 
been focused on the high prevalence of non-adherence (Ascher-Syanum et al., 2009; Novick 
et al., 2010) and the role service user temperaments and perceptions have on adherence 
decisions (Adelugba, Mela, & Haq, 2016; Kamei, Terao, Katayama & Hoaki, 2013; 
Lieberman et al., 2005). The type of health professional also impacts medication judgement 
(Anthierens, Grypdonck, Pauw & Christiaens, 2009; Rochon et al., 2007; Sawan et al., 
2017). Nursing staff have been observed to identified more non-pharmacological 
interventions for managing behaviour than doctors (Geffen et al., 2002) and some front-line 
staff advocate that PRN should only be administered after alternative strategies have been 
attempted (Usher, Baker, Holmes & Stocks, 2009).  
The ethos of best-practice PRN administration is not in contention (NICE, 2014; 
NMC; Royal Pharmaceutical Society, 2007) as it should ideally involve; 1) a collaborative 
decision between the service user and the administrator, 2) be in the service user’s best 
interests, 3) be proportionate to the presenting difficulty and 4) the  benefits should outweigh 
the risks. However, when administering psychotropic PRN medication there are many other 
factors to consider that can obstruct best-practice decision making processes. For example, 
consider a service user that shows no signs of anxiety or agitation at the time of asking for 
a PRN benzodiazepine, has historically been violent towards staff that challenge their need 
for PRN and has been observed to use chemical sedation as a way of avoiding ward 
activities. Making the best judgement on whether or not medication is ‘needed’ for such a 
service user is further complicated by low staffing levels, the staffing mix, level of patient 
risk, quality of the relational security, their rights if under a Section of the Mental Health 
Act (1983) and/or if there are issues around capacity (Mental Health Capacity Act, 2005). 
The Care Quality Commission (2012) reported that 43% of care homes don’t have a 
policy on the use of psychotropic PRN administration. Furthermore, 13,800 care homes in 
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England (NICE, 2014) don’t have in-house nursing services and therefore the administration 
of controlled drugs is done by support workers with sufficient but minimal training (Fretwell 
& Felce, 2007; Morris & Stuart, 2002). Even in services that have highly trained and 
experienced mental health nurses who are supported by a multi-disciplinary team of 
professionals, the judgement of ‘when needed’ remains an unstructured clinical judgement 
for which the accuracy, reliability and consistency may be questionable. If PRN medication 
administration is to move towards an evidence-based approach and if training and 
supervision programs aspire to meet the needs of real-world practitioners then it is important 
to better understand how staff perceive the challenges of PRN medication administration. 
To the authors’ knowledge this is the first study to qualitatively explore the perception of 
ward staff in a care home setting towards the use of psychotropic PRN medication.  
 
Method 
Design  
Due to little being known about how ward staff perceive their administration of 
psychotropic PRN a qualitative design is appropriate because it allows for an analysis of the 
data that is not constrained by theory or quantitative measures. The guiding research 
question was; what do staff know and how do they experience and perceive PRN 
psychotropic medication in their workplace. The collection of this data also allows for an 
exploration of how the current guidelines pertaining to the administration of PRN are 
implemented in practice.  
 
Context and Participants  
This study was conducted in a residential care setting in South Wales that meets the 
needs of eight service users with various mental health conditions including but not limited 
to Schizophrenia, Schizoaffective disorder and Bi-polar. The unit consists of four staff by 
day (three support workers and one shift leader) supported by a senior support worker, 
deputy manager and registered manager. During the night there are two support workers. 
The organisation has a clinical team that consists of clinical nurses and behavioural advisors 
that is in regular contact with the unit involved. However, external professionals from the 
national health services such as psychiatrists, occupational therapists, clinical psychiatric 
nurses and social workers also provide input as needed. Participants were selected through 
convenience sampling as the second author worked in the organisation at the time of data 
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collection. Inclusion criteria was that the participants had to be over 18 and have experience 
in in the decision making process pertaining to the administration of psychotropic 
medication in the workplace. The sample included three men and seven women, experience 
of the participants ranged from nine months to ten years. One of the participants had not 
physically administered PRN medication but had been involved in the decision making 
process.   
 
 PRN Administration Procedure At Site 
 Staff administration of PRN at the research site is governed by their medications 
policy. All service users in receipt of PRN medication have an associated form that provides 
guidelines on the frequency, dosage, time interval between doses, maximum dose in 24 
hours, purpose of administration, other medications to be aware of, special instructions and 
a date for when the form should be reviewed.  This form is signed by the service users key 
worker and a senior member of staff, such as the registered manager. The guidelines are then 
forwarded to the regional clinical team for approval. The policy states that when anti-
psychotic PRN is administered in response to a behavioural incident the full details of the 
events leading up to the incident and why PRN was administered need to be documented. 
When psychotropic PRN medication is administered for anxiety and/or behavioural issues 
the guideline form must be in place and two medication trained staff members must agree 
to administer the medication.  
 
Materials 
Semi-structured interviews with open-ended questions were used to guide but not 
constrict the responses of the participants (Smith & Eatough, 2008). After the first 
participant interview the list of questions were expanded with more prompts to gather a 
greater array of data. The specific questions and prompts to address this question are 
provided in Table 1.  
 
Table 1: Semi-Structured Interview Questions 
Topic: Knowledge of topic area (PRN medication) 
Can you tell me what you know about medication in general?  
How does psychotropic PRN differ from other medication? 
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Prompts included: guidelines, administration, qualification, types and side effects 
Is there anything you feel you don’t understand about psychotropic PRN? 
Topic: Experience 
Can you describe your experiences of administering psychotropic PRN? 
 Prompts: Who usually decides to administer? How often do you administer?  
What would you say is the most common reason for administration? 
 Prompt: Does it usually help? If so how? 
Can you give me examples of one positive and one negative experience that you have had 
with administering this type of medication? 
 If not, what would you think of as being a bad or good experience? 
Topic: Perceptions 
What do you think is the main purpose of psychotropic PRN? 
What is your overall opinion on psychotropic PRN medication? 
 Prompts: How affective do you think it is? Do you feel your service users benefit 
the from PRN medication you administer? 
Do you think there is any difference in the administration of psychotropic PRN medication 
and other general forms of PRN medication e.g. antipsychotic compared with pain relief? 
Can you tell me some good and bad points about PRN medication  
Do you think all staff in healthcare all have the same view on psychotropic PRN 
medication? 
 Prompts: If not, what different views are there? What is your view on this? 
Would you feel comfortable taking this form of medication yourself if you were told you 
needed to and why? 
 
Ethics and Procedure 
Ethical approval was granted by Cardiff Metropolitan University School of Health 
Sciences Research Ethics committee. Participants were greeted in a private room at the 
treatment facility and provided with an information sheet and the opportunity to ask 
questions. After obtaining written informed consent the interviews lasted approximately 20-
40 minutes and were recorded using a smartphone with Samusung S7 Voice Recorder 
version 20.1.86.12 software. Participants had the right to withdraw their involvement and/or 
data until the completion of the project. Participants had the right to refuse to answer 
questions they did not want to answer. The audio recordings were removed from the device 
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following transcription and the final transcripts were kept in a password protected digital 
file.  
 
Theme Construction  
The following stages were used to gather the data for the thematic analysis. Stage 
one involved reading and re-reading all the data and highlighting issues relevant to the 
research question in order to increase familiarisation with the data. Stage two involved using 
Nvivo software (Version 11) to code the data into 51 nodes each with their own title 
description. The amount of data for each node varied from 1-45 data points. Stage 3 aimed 
to organise the nodes into themes based on a combination of topic frequency, similarity and 
importance. Stage four involved independently reviewing the relevance and coherence of 
the data points to the proposed themes and the distinction and structure between themes with 
the research supervisor (first author). 
 
 
Results 
Four themes each with sub-themes emerged; Behaviour Change, Calming Effect, 
Importance of Timing and Perceived Uniqueness. The following provides descriptions and 
illustrative examples from the transcripts. The verbal utterances, such as um’s and ar’s as 
found in the verbatim quotes were removed from the examples below to improve ease of 
reading.  
 
Theme 1: Behaviour Change 
The concept pertaining to behaviour change was the most common in the data 
appearing in all interviews with 42 references. Participants seem to perceive that the main 
purpose of psychotropic PRN medication is to help the service user manage their behaviour. 
Some participants noted a change in the service user’s behaviour as the justification for PRN 
administration (e.g. “you can see that they’re coming off baseline…” (T8, Pg. 4, Ln. 142-
143) and others noted a change in the service user’s behaviour as being indicative of the 
effectiveness of the drug (e.g. “When they stop [the behaviour] you know it’s working” (T3, 
Pg. 5, Ln. 180). 
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Behaviour Change Sub-Theme 1: Specific Emotions. 
When asked under what conditions they would consider PRN administration, three 
specific emotions were repeatedly identified among the data; anxiety, aggression and 
agitation, and occasional reference to psychotic phenomena such as hallucinations. This 
implies that some staff did understand the link between behavioural difficulties and 
underlying emotional and/or perceptual experiences.  
 
Participant 6: “Aggressive behaviour, hallucinations, I dunno if somebody was really 
like upset and like anxious and like if they were gonna harm themselves, I would administer 
a PRN straight away” (T6, Pg. 6, Ln. 234-237). 
 
It was also apparent that participants were often focused on the observable 
behavioural aspects when seeking justification for administration.  
 
Participant 4: “…the client had come out and thumped the wall and dented all the 
wall… we then you know tried to diffuse the situation and administer, I think it was diazepam 
PRN” (T4, Pg. 5, Ln. 180-183). 
 
Behaviour Change Sub-Theme 2: Person-Centred Administration. 
Participants made reference to service-user specific knowledge that guided 
administration decisions, which is in accordance with best practice.  It was often commented 
that what may be classified as an abnormal behaviour for one individual was not abnormal 
for another.  
 
Participant 5: “Like baseline for her, it’s normal for her to be having like the word 
salad… be a little bit sort of low. But it was when her behaviours went really bizarre that I 
think we used to obviously step in and try and give the PRN” (T5, Pg. 5, Ln. 193-196). 
 
Participant 9: “…it’s very much dependant on the, the individual’s own issues” (T9, 
Pg.4, Ln. 126-128). 
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Participants also appeared to believe that without prior knowledge of the service user 
it can be difficult to determine when administration of PRN would be appropriate. 
 
Participant 7: “...you’d administer because there’s another member of staff there 
who knows the client and so I actually think knowing the client is the key to administering 
any sort of PRN” (T7, Pg. 5, Ln. 186-191). 
 
Theme 2: Calming Effect 
Much of the data referred to the calming effect of PRN medication. A frequently 
used phrase by participants was “at baseline”, which refers to the service-users being in a 
positive, relaxed and contented state with an absence of emotional and/or behavioural 
agitation. Participants appeared to see the role of PRN medication to be, in part, to help 
service users return to “baseline”.  
 
Participant 6: “Well the positive would be you know of it working and the client that 
you’re giving it to has calmed down and like come back to baseline or like they, you know, 
they’re not anxious anymore” (T6, Pg. 9, Ln. 323-326). 
 
Participant 5: “[PRN] will make the client feel happier, calmer, more at ease because 
they know they’re having the medication they’re gonna feel better, psychologically it’s better 
for them” (T5, Pg. 11, Ln. 426-430). 
 
When this calming effect doesn’t happen some participants render PRN as 
ineffective because the perceived purpose of it was to bring them back to baseline.  
 
Participant 7: “a positive side is not to see them hurt themselves and watch the drug 
kick in so it calms them… and the negative side I’ve seen then is, we’ve given them but 
they’re just so high that it don’t work at all.” (T7, Pg. 6, Ln. 192-196). 
 
Calming Effect Subtheme: Limiting Side Effects. 
Despite PRN having a calming effect it was also acknowledged by participants that 
there were limits to this effect. Relaxation could increase to the point of sedation and this 
maybe an unhelpful side effect of the medication.  
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Participant 3: “it just makes her sleep all the time and she, you know it’s not working 
for her” (T3, Pg. 4, Ln. 131-132). 
 
Participant 2: “Because of the side effects, say like drowsiness and stuff like that… I 
just can‘t imagine it’s a very nice feeling” (T2, Pg. 3, Ln. 96-98).  
 
Theme 3: Importance of Timing 
Another emergent theme from the data was that participants can find it difficult to 
determine when a psychotropic PRN medication should be administered. The dilemma 
appears to be whether to administer PRN as preventative or only if an incident is occurring. 
In either instance it is influenced by the level of understanding of the service user.  
 
Participant 10: “Some clients, like we work with obviously, soon as they do a step 
different it’s like “oh they’re going”. It’s like, do you give it there or do you wait for her [to 
demonstrate a risk behaviour] before you give it like, it’s that knowing the difference it is, 
but not many people can answer that either” (T10, Pg. 3, Ln. 81-87). 
  
The clinical dilemma for participants appeared to be: what level of symptom or 
behavioural severity justifies the need for psychotropic PRN medication for that particular 
service user. For some service users the focus may need to be on early administration 
whereas for others it might be best given later.  
 
Participant 10: “It’s like, how far do you push it before you actually give it?” (T10, 
Pg. 3, Ln. 77-79). 
 
Participant 6: “It all depends on the person and how bad they are really, when you’re 
administering it” (T6, Pg. 8, Ln. 294-295). 
 
Importance of Timing Subtheme 1: Early Administration. 
For many of the participants it seemed self-evident to them that for some service 
users early administration is the key to reducing risk behaviours and minimising distress. 
Participants believed that they needed to administer PRN at the time of the initial 
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manifestation of symptoms to ensure the effectiveness of the medication. Participants refer 
to these manifestations as “early warning signs” or “moving from baseline”. If early 
administration is not achieved then participants noted that the medication is unlikely to have 
an effect. 
 
Participant 4: “It depends on the person, the medication and how early on it’s used 
really. You know if you picked up all the warning signs early enough then yeah it would be 
more effective than if it’s left hours and hours later” (T4, Pg. 8, Ln. 267-270). 
 
Participant 9: “Ah well that guy…he would become challenging to everybody that he 
pretty much saw, so obviously that, had to address that early” (T9, Pg. 4, Ln. 143-145). 
 
Participant 5: “Once the person is already up there, giving the medication it’s gonna 
have limited effect” (T5, Pg.6, Ln. 205-206). 
 
Participant 7: “We’ve administered PRN medication too late, … and it hasn’t work 
and the incident became challenging and we had to use [physical intervention] to diffuse 
the situation. Which obviously then affects the client” (T7, Pg. 8, Ln. 299-302) 
 
Importance of Timing Subtheme 2: PRN as a Last Resort 
Data in the transcripts also demonstrated that despite the perceived effectiveness of 
early PRN administration it was still considered as a last resort intervention. It was 
advocated by participants that other non-pharmacological interventions should be attempted 
first.  
 
Participant 4: “I wouldn’t just, you know, if I thought somebody was… in a low 
mental state then I just wouldn’t, my first thing wouldn’t be PRN, it would be chat to them 
you know, try and find out what’s going on, why they’re feeling like they are…[PRN] it’s 
like a last resort…” (T4, Pg. 7, Ln. 225-229). 
 
Participant 2: “[PRN] can be given, I think, for the wrong circumstances instead of 
being a last resort they can be given when maybe other things would work or help that 
person” (T2, Pg. 5, Ln. 185-188). 
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Participant 7: “I know this client, let’s take him or her out in the car, for a walk, an 
ice cream, let’s do that thing they like and they can diffuse it…” (T7, Pg. 9, Ln. 350-353). 
 
Importance of Timing Subtheme 3: Organisational Influence  
Despite the lack of national guidelines pertaining to PRN medication decision 
making, many of the participants referred to the policies of their organisation and made 
reference to them. Some participants believed that PRN medication was a ‘last resort’ 
intervention as directed by their organisation. However, there appeared to be some 
uncertainty regarding how to interpret the flexibility of these policies.  
 
Participant 4: “We’ve got guidelines and policies we’ve got to follow anyway and it 
does state in there you know [PRN] should be a last resort, you should find other ways of, 
you know sitting down and speaking to them, see if you can, see if there’s another way…” 
(T4, Pg. 7, Ln. 237-241). 
 
Participant 9: “I think we are, we can be reluctant to use them because sometimes 
our own guidelines state that [PRN] is last resort” (T9, Pg.6, Ln. 198-200). 
 
Theme 4: Perceived Uniqueness of Psychotropic PRN 
The majority of participant perceived psychotropic PRN medication as a unique form 
of medication, a strong drug that “alters people’s minds”. There is also mention of how it 
cannot be purchased over the counter like some other forms of PRN medication, which 
seems to reinforce this perception of importance.  
 
Participant 6: “Because… like a paracetamol and a co-codamol is just like a pain 
relief, like a pain killer so you can buy them over the counter and stuff like that” (T6, Pg. 9, 
Ln. 303-305). 
 
Participant 4: “Because they’re antipsychotics… they’re … an important drug… if 
that makes more sense?” (T4, Pg. 4, Ln. 111-113). 
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Participant 7: “Because its psychotropic medication, it alters the mind. It’s scary 
stuff” (T7, Pg. 7, Ln. 270-271). 
 
Participant 9: “A quantum step up from a normal pain medication or something like 
that, seems a whole lot different” (T9, Pg. 6, Ln. 213-215). 
 
Perceived Uniqueness Subtheme 1: Greater Staff Responsibility. 
Participants noted that decisions pertaining to PRN administration required a 
substantial amount of clinical responsibility. The need for shared decision making was noted 
but in practice decisions were typically made by one person. Participants also made 
reference to difficulties that can arise when service users are not requesting PRN but the 
staff suspect that the service user may need it. The pressures of responsibility appear to be 
particularly highlighted for those who are not registered nurses.  
.  
Participant 9: “I have always found the best approach is, is to, to try and at least get 
some agreement [with staff] that they do need some sort of help” (T9, Pg. 7, Ln. 238-241) 
 
Participant 10: “[Service-user name] couldn’t even talk [due to depression] so it 
would be some staff going “oh well I think he needs it”. Like how do you know though?” 
(T10, Pg. 4, Ln. 135-138) 
 
Participant 5: “I definitely feel like there’s a reluctance to give mental health PRN’s 
in my experience, like, as being a support worker” (T5, Pg. 4, Ln. 130-132). 
 
Perceived Uniqueness Subtheme 2: Recreation or Therapeutic. 
A final aspect that seemed to emerge in respect to the uniqueness of psychotropic 
PRN medication was the perception that there is a risk it can be used recreationally. It was 
perceived by some participants that some service users like the effect of the medication and 
this pleasure was their motive for using PRN. Making collaborative decisions that are in the 
long-term best interests of the service users can be extremely challenging under such 
circumstances.  
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Participant 5: “Some clients ask for PRN when it doesn’t appear that they do actually 
need it, because they like the effect of the medication and I think staff are aware of that and 
don’t want that to become a normal practice” (T5, Pg 7, Ln. 258-261). 
 
Participant 7: “[Service user name] might ask for it when she’s low because she 
wants it not needs it, but then when [she] needs it she won’t ask for it” (T7, Pg. 10, Ln. 360-
363). 
 
Discussion 
This study was designed to explore the perceptions of staff in a residential care 
setting towards psychotropic PRN medication. Thematic Analysis of the transcribed 
interviews led to the identification of four themes; Behaviour Change, Calming Effect, 
Importance of Timing and Perceived Uniqueness, each with practical implications for 
clinical practice, teaching and organisational policies. The purpose of psychotropic PRN 
medication is to reduce acute mental health symptoms such as panic, agitation and/or 
psychosis. If effective the medication is likely to change the service user’s internal mental 
state, which should in turn change their behaviour. However, as the Behavioural Change and 
Calming Effect themes highlight, the observer is at risk of perceiving the function of PRN 
medication to be to change service user behaviour rather than to change their internal mental 
state. This is an important distinction because if the focus is only on attempting to modify 
behaviour by means of pharmacology then the function and formulation of that behaviour is 
at risk of being overlooked.  
Future medication training programs may benefit from helping staff to understand 
the complex indirect impact that PRN medication has on behaviour. Making these causal 
links explicit to staff in organisational policy may help prevent staff cultures from 
developing in which PRN is used as a means of behavioural control, as has been the case in 
other services (Vander Stichele et al., 2006). Furthermore, such an approach by the staff may 
help service users understand that medication is helpful when it effects mental state and 
should not be used as a means of psychological and/or behavioural avoidance. In the 
residential unit in this study their PRN Guidance Form allows for an explanation of how and 
when the medication is to be administered, which is in keeping with best practice (Matthias, 
Salyers, Rollins & Frankel, 2012; NICE, 2014; NMC).  
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The importance of appropriate PRN administration timing was a main theme in the 
data. Participants in this study showed judicious and proportionate decision making 
practices with regards to PRN administration for their service users. Providing service users 
with the opportunity for early PRN administration may help to reduce the escalation of 
distress, reduce risk behaviours and be more beneficial for them than waiting until extreme 
behavioural disturbances manifest. However, this needs to be done in accordance with 
service user specific knowledge and within an organisational culture that supports the use 
of non-pharmacological interventions before PRN. Policies pertaining to PRN 
administration should therefore emphasise the importance of relational security, service user 
specific formulations, the need for alternative treatment options and appropriate early 
administration practices commensurate with the risks and potential side effects of the 
medication. Acute PRN medication is often used as a rapid form of sedation (Duxbury & 
Whittington, 2005) in order to reduce the risk of service users harming themselves or others 
(Brown, Chhina & Dye, 2010). The calming effect of PRN medication theme reflected this 
notion. In this participant group sedation was appropriately perceived as a risk to the service 
user that could undermine their overall treatment but if used correctly could greatly benefit 
them. 
Despite the potential benefits PRN medication may bring to service users there is 
contrary evidence that suggests the overall impact maybe detrimental. Thapa et al. (2003) 
reported on the findings of a hospital whereby psychotropic PRN medication was stopped 
for three months and found that there were fewer incidents of aggression, seclusion, and 
restraint yet no compensatory increase in regular medication. Smith et al. (2008) expanded 
prior research across nine hospitals and imposed a 15-month ban on all PRN medication 
unless the physician conducted a face-to-face or telephone assessment of the service user 
within one hour and provided the drug is approved for that specific presenting symptom. 
The results showed that the frequency of aggressive behaviours was reduced, restraints 
reduced and there was no overall increase in regular medication. The results also 
demonstrated greater collaboration between physician and ward staff, and nursing staff were 
better able to focus on supporting the service users instead of completing PRN related tasks. 
Such studies are not always possible given the level of risk some service users pose but it 
does highlight how the evidence base pertaining to effective PRN administration is far from 
established and remains in contention.  
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The following is a summary pertaining to the management of psychotropic PRN 
medication built on current guidelines (NICE, 2014; NMC; Royal Pharmaceutical Society, 
2007) and related research (Smith et al., 2008; Thapa et al., 2003).  
 
1. Decisions on whether or not to use PRN medication should ideally be made 
collaboratively between the physician, administrator and the service user where possible. 
PRN decisions are best made when they are service-user specific involving a unique 
formulation of the service user and specific guidance on when early administration is in 
the best interests of the service user. 
2. PRN should only be given if it is licenced for that specific difficulty and in proportion 
with the severity of the presenting difficulty. It is important for staff to be aware of the 
limited evidence base and contraindicative findings for PRN medication in the literature 
at this point in time. If PRN is in regular use then it should be added to their regular 
medication and removed from PRN.  
3. Record keeping: Physicians should document how and why PRN medication is to be 
administered. Administering staff should document their rationale for administering PRN 
and the service user’s presentation following administration. 
4. Organisations have a responsibility to be aware of and manage the factors that can 
compromise best-practice decision making, which include but are not limited to; lack of 
staff training, inexperienced and/or unfamiliar staff, a lack of staff and a lack of 
alternative treatments. 
  
The following are suggestions for improvement based on the findings of this study;  
1. Clinical Practice 
a. Greater Multi-disciplinary Team working and formulation is needed to develop 
collaborative plans for when medication is used and under what circumstances.  
b. Better systems of monitoring and understanding the side effects of PRN is needed 
for each patient. For example, if a service user has had PRN administered because 
they were physically agitated due to hallucinations and they now appear calm it 
does not necessarily mean that the hallucinations have improved.  
2. Teaching 
a. More education on mental state, side effects, alternative coping strategies and 
developing unique service-user formulations are needed.  
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b. Further training/workshops in making advanced complex decisions around PRN 
administration.   
3. Organisational 
a. All organisations need to have a policy on how they will manage PRN in their 
service 
b. Blanket rules and organisational culture on using PRN as a last or first intervention 
need to be removed from policies because each management plan should be 
service-user specific.  
 
Future research could address some of the limitations of this study by qualitatively 
examining the perceptions of larger homogenous groups of staff such as nursing, psychiatry 
and psychology, in a range of different settings including forensic, acute mental health, 
prison, care homes and the community. Quantitative research could be used to explore the 
actual rates of usage and the factors that correlate with administration. The culmination of 
such research could be used to guide policy and clinical practice on psychotropic PRN usage. 
Alongside such research it will be important to evaluate the effectiveness of PRN medication 
for services users as well as review the economic costs of administration. Together these 
elements will determine the usefulness of PRN in practice. This study is the first thematic 
analysis of staff perceptions towards the administration of psychotropic PRN medication in 
a residential care setting. The findings uniquely highlight the complex challenges facing 
staff trying to make best practice decisions regarding the administration of psychotropic 
PRN medication. 
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